Hetrombopag Olamine

DRUG14 trials

Sponsors

Jiangsu Hengrui Pharmaceuticals Co. Ltd., Jiangsu HengRui Medicine Co., Ltd., Huazhong University of Science and Technology, RenJi Hospital, Sir Run Run Shaw Hospital

Conditions

Chemotherapy induced thrombocytopeniaChemotherapy-Induced ThrombocytopeniaChronic Idiopathic Thrombocytopenic PurpuraHealthyIdiopathic Thrombocytopenic PurpuraImmune ThrombocytopeniaMalignant Tumors of the Digestive SystemPatients With Chemotherapy-Induced Thrombocytopenia

Phase 1

A Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients

Jiangsu HengRui Medicine Co., Ltd.Purpura, Thrombocytopenic, Idiopathic

Start: 2014-04-30Target: 24Updated: 2015-03-31

Effect of a High-fat Meal on the Pharmacokinetics of Hetrombopag and Mass Balance Study in Healthy Subjects

CompletedNCT02409394

Jiangsu HengRui Medicine Co., Ltd.Healthy

Start: 2014-03-31End: 2014-04-30Updated: 2015-04-06

Safety and Efficacy Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients

Jiangsu HengRui Medicine Co., Ltd.Chronic Idiopathic Thrombocytopenic Purpura

Start: 2015-08-31Target: 29Updated: 2015-11-25

A Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Severe Aplastic Anemia （SAA） Patient

CompletedNCT03557099

Jiangsu HengRui Medicine Co., Ltd.Severe Aplastic Anemia

Start: 2018-06-20End: 2020-07-23Updated: 2022-07-29

A Study to Evaluate Different Intervals Between Dosing and Feeding on the Pharmacokinetics

CompletedNCT03603132

Jiangsu HengRui Medicine Co., Ltd.Immune Thrombocytopenia

Start: 2018-07-14End: 2018-08-17Updated: 2019-05-07

Metabolism and Disposition of [14C] Herombopag in Chinese Healthy Human Subjects

CompletedNCT03977805

Jiangsu HengRui Medicine Co., Ltd.Healthy

Start: 2019-05-25End: 2019-06-13Updated: 2020-05-08

Phase 2

Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia(CIT) in Patients With Acute Myeloid Leukemia

Not yet recruitingNCT05944211

RenJi HospitalChemotherapy-Induced Thrombocytopenia

Start: 2023-07-31End: 2027-01-31Target: 72Updated: 2023-07-13

Hetrombopag for the Thrombocytopenia Induced by Concurrent Chemoradiotherapy

RecruitingNCT06433830

Sir Run Run Shaw HospitalRadiotherapy Side Effect, Thrombocytopenia

Start: 2022-05-10End: 2025-07-30Target: 50Updated: 2024-05-30

TPO-RA Treatment on Immune Tolerance Induction of ITP Patients With Sustained Platelet Recovery After Treatment Termination

RecruitingNCT06478537

Peking Union Medical College HospitalImmune Thrombocytopenia

Start: 2024-06-20End: 2027-06-20Target: 56Updated: 2024-06-27

Phase 3

Multicentre, Randomised Phase III Study of the Efficacy and Safety of Hetrombopag Olamine in Idiopathic Thrombocytopenic Purpura (ITP) Patient

CompletedNCT03222843

Jiangsu HengRui Medicine Co., Ltd.Idiopathic Thrombocytopenic Purpura

Start: 2017-06-30End: 2021-01-07Updated: 2022-08-03

Extension Study of Hetrombopag in Severe Aplastic Anemia

Active, not recruitingNCT04961710

Jiangsu HengRui Medicine Co., Ltd.Treatment-naive Severe Aplastic Anemia

Start: 2019-09-19End: 2024-12-31Updated: 2024-09-19

A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia

RecruitingNCT07286032

Jiangsu HengRui Medicine Co., Ltd.Patients With Chemotherapy-Induced Thrombocytopenia

Start: 2026-04-16End: 2029-06-01Target: 150Updated: 2026-07-14

A Randomized, Multi-Center, Double-Blind, Phase III Study Evaluating the Efficacy and Safety of Hetrombopag Olamine Tablets vs Placebo in Patients with Chemotherapy-Induced Thrombocytopenia

Not yet recruitingCTIS2025-524209-34-00

Jiangsu Hengrui Pharmaceuticals Co. Ltd.Chemotherapy induced thrombocytopenia

Target: 19Updated: 2026-04-22

Phase 4

Herombopag Olamine in the Treatment of Thrombocytopenia After Chemotherapy

Huazhong University of Science and TechnologyMalignant Tumors of the Digestive System, Trombocitopenia

Start: 2022-10-31End: 2023-12-31Target: 40Updated: 2022-10-12

Related Papers

Hetrombopag in patients with chemotherapy-induced thrombocytopenia: A global phase 3, randomized, double-blind study.

Journal of Clinical Oncology2026-05-28

Hetrombopag for patients with persistent primary immune thrombocytopenia: A post-hoc analysis of a multicenter, randomized phase Ⅲ Trial

Blood2025-11-03

Hetrombopag for patients with persistent primary immune thrombocytopenia: a post hoc analysis of a multicenter, randomized phase Ⅲ trial.

2025-10-07

Hetrombopag Added to Immunosuppressive Therapy in First-Line Treatment of Severe Aplastic Anemia: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial

Blood2024-11-051 citations

Switching from Eltrombopag to Hetrombopag in Patients with Primary Immune Thrombocytopenia (ITP): Post-Hoc Analysis of a Multicenter, Randomized Phase III Trial

Blood2022-11-151 citations

Iron chelation of hetrombopag in aplastic anemia: a post hoc analysis of a phase II study.

2022-10-115 citations

A multicenter phase II study on the efficacy and safety of hetrombopag in patients with severe aplastic anemia refractory to immunosuppressive therapy

Therapeutic Advances in Hematology2022-01-0129 citations

Safety and efficacy of hetrombopag in patients with chronic immune thrombocytopenia: a single-arm, open-label, multi-center phase 1 study.

2022-01-012 citations

Dose tapering to withdrawal stage and long-term efficacy and safety of hetrombopag for the treatment of immune thrombocytopenia: Results from an open-label extension study.

2021-12-158 citations

A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia.

2021-02-2547 citations

A Multicenter, Open-Label, Single-Arm, Phase 2 Study to Evaluate the Efficacy and Safety of Hetrombopag in Patients with Severe Aplastic Anemia (SAA)

Blood2020-11-057 citations

Effect of Food on the Pharmacokinetic and Pharmacodynamic Profiles of Hetrombopag in Healthy Volunteers.

2020-10-248 citations